Triazolopyrimidine cannabinoid receptor 1 antagonists
AssigneeBristol-Myers Squibb Company
InventorsGang Wu, Amarendra B. Mikkilineni, Philip M. Sher, Natesan Murugesan, Zhengxiang Gu
Life of this patent
Estimating the term…
Abstract
The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
Claims3
A compound according to Formula I
- or a pharmaceutically acceptable salt or a stereoisomer thereof
- wherein
- R1 is selected from the group consisting of phenyl and pyridyl which may each be optionally substituted with 1 to 3 members selected from the group consisting of halogen, cyano, alkyl and hydroxyalkyl;
- R2 is phenyl which may be optionally substituted with 1 to 3 halogen;
- R3 is an alkyl which may be optionally substituted with 1 to 3 R10;
- R4 is selected from the group consisting of hydrogen, halogen, cyano, alkyl, alkoxy, —S—CH3, NH2, NHCH3, NCH(CH3)2,
- R10 in each instance is independently selected from the group consisting of alkyl, phenyl, pyridyl, halogen, and cyano, wherein the alkyl, phenyl and pyridyl may each be optionally substituted with 1 to 3 members selected from the group consisting of halogen, cyano, hydroxyl, carboxyl, CF3, and
A compound is selected from the group consisting of:
Dependencies are inferred from the claim text.